drugset / Trial / NCT04037176

Behandling af Boern Med Foedevareallergi Med Omalizumab (Xolair)

NCT04037176

RandomizedParallel-groupTriple-blindTreatment

Summary

Food allergy is a common disease in childhood affecting up to 8% of children in Westernized countries. About 30 percent of children with food allergies are allergic to more than one food, most often milk, egg, wheat, peanut and tree nut. Peanut and hazelnut are common triggers of severe and potentially fatal food-induced anaphylactic reactions. Currently, there is no curative treatment for food allergy. Novel therapies for this potentially life-threatening condition are therefore much needed.

Timeline

Start
2019-11-01
Primary completion
2022-03-15
Completion
2022-03-15

Drugs

EvaluationDrugModalityDoseRoute
Comparator Omalizumab Monoclonal antibody Subcutaneous

Indications